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Intracellular Inactivation of the Hepatitis B Virus
by Cytotoxic T Lymphocytes
Luca G. Guidotti,*³ Tetsuya Ishikawa,* lymphocytic choriomeningitis virus (LCMV), the proto-
typic noncytopathic virus that requires CTL for clear-Monte V. Hobbs,² Brent Matzke,* Robert Schreiber,§
and Francis V. Chisari* ance (Byrne and Oldstone, 1984). For example, perforin-
deficient mice are unable to clear certain LCMV strains*Department of Molecular and Experimental Medicine
²Department of Immunology (KaÈ gi et al., 1994; Walsh et al., 1994), thus suggesting
that the specific destruction of infected cells by CTL isThe Scripps Research Institute
10666 Torrey Pines Road required for viral clearance. However, the same strains
of LCMV replicate uncontrollably in mice that lack IFNgLa Jolla, California 92037
³Istituto di Patologia Generale receptors (MuÈ ller et al., 1994) or that have been treated
with IFNg-specific antibodies (Moskophidis et al., 1994),UniversitaÂ degli studi di Parma
43100 Parma suggesting that clearance of LCMV also requires the
production of this cytokine and perhaps others. Further-Italy
more, LCMV infection in mice can be cleared, without§Department of Pathology
evidence of cytopathology (Gegin and Lehmann-Grube,Washington University School of Medicine
1992), before the onset of detectable cytolytic activitySt. Louis, Missouri 63110
and by extremely small numbers of adoptively trans-
ferred CTL (Lehmann-Grube et al., 1985).
In hepatitis B virus (HBV)-infected humans, viral clear-
ance is associated with the development of a vigorousSummary
cellular immune response and an acute necroinflamma-
tory liver disease, termed viral hepatitis (reviewed byIt is widely believed that viral clearance is mediated
Chisari and Ferrari, 1995). Hence, it is widely assumedprincipally by the destruction of infected cells by CTLs.
that HBV clearance is mediated principally by the de-In this report, we use a transgenic mouse model of
struction of infected cells by virus-specific MHC classHBV replication to demonstrate that this assumption
I±restricted CTL. This assumption may be incorrect,may not be true for all viruses. We find that adoptively
however, for at least two reasons. First, the CTL re-transferred virus-specific CTLs can abolish HBV gene
sponse maynot be able to reach, recognize, and destroyexpression and replication in the liver without killing
the vast number of infected hepatocytes (up to 1011 cells)the hepatocytes. This antiviral function is mediated by
in the liver by direct physical contact. Second, HBVIFNg and TNFa secreted by the CTL or by the antigen-
clearance is usually associated with clinical recovery,nonspecific macrophages and T cells that they acti-
not death, despite the fact that the virus can infect virtu-vate following antigen recognition. These cytokines
ally all hepatocytes. Rapid and complete viral clearance,activate two independent virocidal pathways: the first
without massive hepatocellular necrosis, is also the rulepathway eliminates HBV nucleocapsid particles and
following woodchuck hepatitis virus (WHV) infection,their cargo of replicating viral genomes, while the sec-
during which virtually all the woodchuck hepatocytesond pathway destabilizes the viral RNA. Intracellular
are infected (Kajino et al., 1994). For these reasons, weviral inactivation mechanisms such as these could
favor the notion that viral clearance during HBV infectiongreatly amplify the protective effects of the immune
may be mediated by noncytolytic antiviral effects of CTL,response, while failure of such mechanisms could lead
and that the associated liver disease is an unfortunateto viral persistence or to the death of the host.
complication of CTL activation rather than a determining
factor in viral clearance.
The experimental approaches to HBV pathogenesisIntroduction
have been hampered because the host range of HBV is
limited to man and chimpanzees and because cultureThe clearance of intracellular pathogens,especially non-
cytopathic viruses, by the immune response is widely systems for the propagation of HBV do not exist. Re-
cently, however, we produced transgenic mice that rep-thought to be mediated primarily by the destruction of
infected cells by major histocompatibility complex licate the HBV genome and sustain the HBV lifecycle in
their hepatocytes (Guidotti et al., 1995). We now report(MHC) class I±restricted CD81 cytotoxic T lymphocytes
(CTLs). However, upon antigen recognition such CTL that HBV-specific CD81 CTL can abolish HBV gene ex-
pression and replication in the liver of these transgeniccan also secrete potent antiviral cytokines such as inter-
feron-g (IFNg) and tumor necrosis factor-a (TNFa), which mice while killing only a small fraction of the hepato-
cytes. This effect is mediated by inflammatory cytokinescan potentially cure viral infections without killing the
infected cells. The importance of noncytodestructive such as IFNg and TNFa, apparently activating the hepa-
tocytes to eliminate cytoplasmic HBV nucleocapsid par-curative functions of CTL in viral clearance is not known,
but has been implied by indirect evidence in the past ticles with their replicating viral genomes and to destabi-
lize the viral RNA, thereby interrupting viral replication.(reviewed by Lehmann-Grube et al., 1988; Martz and
Howell, 1989). The relative importance of cytodestruc- All of these events occur in perfectly viable hepatocytes




Adoptively Transferred CTLs Kill a Small
Fraction of HBV-Positive Hepatocytes
in the Transgenic Mouse Liver
Age- and serum HBsAg-matched transgenic males from
lineages 1.3.32 and 1.3.46 (H-2d) were injected intrave-
nously with various numbers of several independently
derived CD81 Ld-restricted HBsAg-specific CTL (Ando
et al., 1993; Guidotti et al., 1994a). These mice express
all of the HBV antigens, including HBsAg, in the vast
majority of their hepatocytes (Guidotti et al., 1995). As
exemplified in Figure 1A for CTL clone 6C2 and lineage
1.3.32, all CTL clones produced a mild, transient, cell
dose±dependent necroinflammatory liver disease in
both lineages, monitored biochemically as serum ala-
nine aminotransferase (sALT) activity, a hepatocellular
enzyme that is released into the circulation by necrotic
hepatocytes. sALT levels began to rise within a few
hours of CTL administration, reached maximum severity
by day 3, and returned to baseline within 1 week. As
expected, disease severity was CTL dose dependent;
yet sALT activity was only modestly elevated in mice
receiving the highest number (1 3 107) of cloned CTL
(Figure 1), compared with previously reported mouse
models of liver disease (Ando et al., 1993).
To estimate the fraction of total hepatocytes that are
destroyed by the CTL during this disease, we compared
the ALT profile of the CTL-injected mice with the ALT
profile in normal mice that were injected with a lysate
prepared from a known amount of liver. In this manner,
we estimated that no more than 6%, 10%, or 24% of
the hepatocytes were killed following the injection of
2.5 3 106, 5 3 106, and 1 3 107 CTL, respectively (data
not shown).
Histological analysis of the livers at the peak of sALT
activity (day 3) demonstrated necroinflammatory foci
containing dead and degenerating hepatocytes, distrib-
uted principally in the periphery of the hepatic lobule, Figure 1. CTL-Mediated Liver Disease and Inhibition of HBV Gene
Expression Replication: Dose Responseadjacent to the portal veins from which cells enter the
(A) sALT activity (6 SEM) after intravenous injection of increasingparenchyma of the liver (see below). However, the vast
numbers of HBsAg-specific CTL into groups of three mice frommajority of the hepatocytes, especially the centrilobular
lineage 1.3.32 is expressed as units/liter. By comparing these valueshepatocytes that replicate high level HBV in these ani-
with the ALT profile obtained after injection of a known amount of
mals (Guidotti et al., 1995), appeared histologically nor- liver extract, we estimated that no more than 6%, 10%, or 24% of
mal. As a specificity control, 1 3 107 HBsAg-specific the hepatocytes were killed following the injection of 2.5 3 106, 5
CTLs were injected into nontransgenic littermates and 3 106, and 1 3 107 CTL, respectively (see Experimental Procedures).
(B) Effect of CTL on HBV gene expression in lineage 1.3.32. Doseinto transgenic mice from lineage 1.3.32 that lack the
response. Northern blot analysis of 20 mg of total liver RNA isolatedH-2d restriction element utilizedby the CTL.No biochem-
from three groups of two mice 5 days after intravenous injection ofical or histopathological evidence of liver disease was
increasing doses of CTL, as indicated. The steady-state HBV and
observed in any of these animals (data not shown). GAPDH mRNA content was compared with total RNA pooled from
10 age-, sex-, and serum HBsAg-matched transgenic saline-injected
controls, as indicated.
Adoptively Transferred CTLs Clear All (C) Effect of CTL on HBV replication in lineage 1.3.32. Southern blot
analysis of 20 mg of total liver DNA isolated from the same mice.Traces of HBV Gene Expression and
HBV DNA content was compared with total DNA pooled from theReplication from the Liver and Virions from
same controls described above. All DNA samples were RNAsethe Serum of HBV Transgenic Mice
treated before gel electrophoresis. Bands corresponding to the ex-
Despite the relative mildness of theCTL-induced hepati- pected size of the integrated transgene, relaxed circular (RC), dou-
tis in these animals, and the fact that only a minor popu- ble-stranded linear (DS), and single-stranded (SS) HBV DNA are
lation of hepatocytes was destroyed during the course indicated. Bands corresponding to the integrated transgenes can
be used to normalize the amount of DNA bound to the membrane.of the disease, all traces of viral RNA, replicative DNA
The filters were hybridized with a 32P-labeled HBV-specific DNAintermediates, and nucleocapsid protein (HBcAg) were
probe.eliminated from the liver and serum following the admin-
istration of several different CTL clones. These effects
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were dose dependent and displayed a characteristic completely abolished in mice that received 5 3 106 and
1 3 107 CTL, and they were reduced 2- to 3-fold in micesequential temporal profile.
that received 2.5 3 106 CTL. Note that virtually 100% ofCTL Dose Response
the hepatocytes express the viral RNA in these animalsIn this study, nine age-, sex-, and serum HBsAg-
(Guidotti et al., 1995), yet it totally disappeared whenmatched transgenic mice from lineage1.3.32 (three mice
only 10% of the hepatocytes were killed by the CTLper group) were injected intravenously with 2.5 3 106,
(Figure 1A), suggesting that noncytolytic mechanisms5 3 106, and 1 3 107 HBsAg-specific CTL (clone 6C2),
contributed substantially to this effect.and livers were harvested 5 days later. Histological anal-
To evaluate the effect of CTL dose on HBV replication,ysis revealed that the vast majority of hepatocytes were
Southern blot analysis was performed on total hepaticcytologically normal in all CTL-treated livers at this time-
DNA extracted from the same livers, and HBV DNA con-point (see below), in parallel with the return of serum
tent was compared with total DNA pooled from the sametransaminase activity to normal levels (Figure 1A).
controls described immediately above. Two representa-To examine the effect of CTL dose on HBV gene ex-
tive mice per group are illustrated in Figure 1C. Hepaticpression, Northern blot analysis was performed on total
HBV DNA replicative forms were undetectable in all thehepatic RNA. The most abundant viral transcripts in the
CTL-treated animals, including the mice that receivedliver of these animals are 3.5 and 2.1 kb in length (Gui-
the lowest CTL dose, thus suggesting that the viral repli-dotti et al., 1995). The 3.5 kb HBV transcript serves as
cative DNA intermediates are more responsive to elimi-the messenger RNA for the viral nucleocapsid proteins
nation by the CTL than is the viral RNA. Note that viral(HBcAg and HBeAg) and for the viral polymerase protein,
replication is detectable in at least 30% of the hepato-and it functions as theviral pregenome since it is reverse
cytes in these mice (Guidotti et al., 1995), yet it wastranscribed by the polymerase to produce the first
completely abolished when only 6% of the hepatocytesstrand of viral DNA during viral replication. The 2.1 kb
were killed by the CTL (Figure 1A), and most of these
transcript serves as the messenger RNA for the viral
hepatocytes were located in the periphery of the hepatic
middle and major envelope proteins (reviewed by Ga-
lobule near their site of entry into the liver, not in the
nem and Varmus, 1987). Virtually all of the hepatocytes center of the lobule where replication is most active (see
in these animals express viral RNA and nuclear HBcAg. below), again suggesting that noncytolytic processes
Importantly, the 3.5 kb viral mRNA is most abundant in cause this effect.
the centrilobular hepatocytes, corresponding with the To confirm that HBV mRNA disappears completely
centrilobular localization of cytoplasmic HBcAg parti- from all HBV RNA-positive hepatocytes following CTL
cles and viral replicative intermediates in these livers administration, we performed in situ hybridization analy-
(Guidotti et al., 1995). Centilobular zonation of liver gene sis on liver sections from CTL-injected and uninjected
expression is not uncommon (Lamars et al., 1989) and transgenic mice using an antisense 33P-labeled HBV ri-
is thought to reflect the zonation of transcription factors boprobe that can detect all the overlappingHBV mRNAs.
in the hepatic lobule (Nagy et al., 1994). As shown in Figure 2 (left), lineage 1.3.32 (and 1.3.46,
The hepatic steady-state HBV and glyceralde- data not shown) expresses HBV mRNA in the vast major-
hyde-3-phosphate (GAPDH) mRNA content of CTL- ity of the hepatocytes. However, HBV mRNA was unde-
injected mice was compared with total RNA pooled from tectable 5 days after the administration of 107 CTL in all
10 age-, sex-, and serum HBsAg-matched transgenic of the hepatocytes (Figure 2, right). Consistent with this
controls injected with saline. As shown in Figure 1B for observation, nuclear and cytoplasmic HBcAg also com-
two representative mice per group, the hepatic steady pletely disappeared from the liver within 5 days after
injection of the CTL (see below).state content of the 3.5 and 2.1 kb HBV mRNA were
Figure 2. The CTL-Dependent Down-Regu-
latory Effect on HBV mRNA Extends to All
HBV RNA-Positive Hepatocytes and to All
HBV mRNA Species in Lineage 1.3.32
Detection of HBV mRNAs by in situ hybridiza-
tion analysis on liver sections from transgenic
mice intravenously injected 5 days earlier ei-
ther with saline (left), or with 107 HBsAg-spe-
cific CTL (right). An anti-sense 33P-labeled
HBV riboprobe that candetect all the overlap-
ping HBV mRNAs was used. (Hematoxylin
and eosin; original magnification, 2003).
Cross-sections of the large median lobe from
the indicated mice were placed on film over-




Figure 3. Effect of CTL on Hepatocellular HBcAg
Time course. Age-, sex-, and serum HBsAg-matched transgenic mice (18) from lineage 1.3.32 were injected intravenously with 107 HBsAg-
specific CTL (clone 6C2), and livers were harvested at various timepoints thereafter and stained to detect HBcAg. Necroinflammatory foci are
indicated with arrowheads and mitotically active hepatocytes with asterisks. (Immunoperoxidase stain for HBc/eAg; original magnification,
2003).
Time Course of the liver disease (day 3) approximately 10% of the
hepatocytes displayed PCNA-positive nuclei, subsidingThe foregoing events occurred in phases, first affecting
to less than 1% at day 5 and baseline (less than 0.1%)the cytoplasmic HBcAg, which became undetectable in
at day 14. The relatively minor degree of liver cell regen-centrilobular hepatocytes within 24 hr of CTL adminis-
eration seen in these animals is consistent with the rela-tration, in the absence of centrilobular liver disease, as
tively small number of hepatocytes that were killed byshown in mice that received 1 3 107 CTL (Figure 3B).
the CTL.By day 3, at the peak of liver disease, scattered necroin-
As shown in Figure 4B, HBV DNA replicative formsflammatory foci were detectable in the hepatic lobule,
disappeared from the liver concomitant with the disap-especially in the periphery (Figure 3C, arrowheads), and
pearance of cytoplasmic HBcAg (see Figure 3B),nuclear HBcAg was profoundly reduced throughout the
approximately 2 days before any change in the steady-liver (Figure 3C). By day 5, HBcAg decreased to unde-
state content of the 3.5 kb pregenomic RNA was detect-tectable levels throughout the liver, despite the fact that
able (Figure 4A). Like the decrease in hepatic HBcAgthe vast majority of the hepatocytes were cytologically
content, the duration of this effect was prolonged. In-normal (Figure 3D). HBcAg remained undetectable be-
deed, hepatic replicative DNA intermediates were unde-
yond day 14 and began to reappear, particularly in the
tectable by Southern blot analysis 4 weeks after CTL
cytoplasm of centrilobular hepatocytes, by day 28 (data
injection in one mouse, while they were partially restored
not shown). Similar results were obtained by administra- in the other animal sacrificed at this timepoint (Figure
tion of 1 3 107 HBsAg-specific CTL in lineage 1.3.46 4B). The same profound and prolonged effect was ob-
(data not shown). served in lineage 1.3.46 following the administration of
To evaluate the extent to which hepatocyte turnover 5 3 106 HBsAg-specific CTL (data not shown). These
might contribute to this effect, we monitored the same results strongly suggest that the loss of replicative DNA
liver sections for hepatocellular expression of proliferat- intermediates was linked to the disappearance of nu-
ing cell nuclear antigen (PCNA) as a marker of cells in cleocapsid particles, within which replication occurs,
S phase (Kurki et al., 1988) (data not shown). A slight rather than to a decrease in pregenomic RNA template.
increase in the number of PCNA-positive hepatocytes The disappearance of viral RNA from the liver dis-
played very different kinetics. Northern blot analysis ofwas first observed 24 hr after CTL injection. At the peak
CTL-Mediated Inhibition of HBV Replication
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Figure 4. Effect of CTL on HBV Gene Expres-
sion and Replication in Lineage 1.3.32
Time course. Northern and Southern blot
analysis was performed on total hepatic RNA
and DNA extracted from the same mice de-
scribed in the legend to Figure 3. Groups of
two mice were sacrificed at 4 hr and 1, 2, 3,
5, 7, 10, 14, and 28 days after injection of 107
HBsAg-specific CTL.
(A) Northern blot analysis of 20 mg of total
liver RNA isolated from mice sacrificed at the
indicated timepoints. The steady-state HBV
and GAPDH mRNA content was compared
with total RNA pooled from 10 age-, sex-, and
serum HBsAg-matched transgenic saline-
injected controls.
(B) Southern blot analysis of 20 mg of total
liver DNA isolated from the same mice. HBV
DNA content was compared with total DNA
pooled from the same controls described
above. All DNA samples were RNAse treated
before gel electrophoresis. The filters were
hybridized with a 32P-labeled HBV-specific
DNA probe. DNA loading was normalized by
comparing the signal intensity of the inte-
grated transgene DNA seen at the top of each
lane.
total hepatic RNA extracted from the same livers de- of adoptively transferred HBsAg-specific polyclonalCTL
scribed above revealed that the hepatic steady-state lines in this system. Four age-, sex- and serum HBsAg-
content of the 3.5 and 2.1 kb HBV mRNA was unchanged matched transgenic mice from lineage 1.3.32 were in-
4, 24 (Figure 4A), and 48 hr (data not shown) after CTL jected intravenously with 107 lymphocytes from a short-
injection. By day 3, however, HBV mRNA content de- term polyclonal CTL line derived by 2 weeks of in vitro
creased, reaching almost undetectable levels by day 5 antigen stimulation of HBsAg-primed spleen cells from
when disease activity had nearly completely subsided. a B10.D2 mouse. The mice were bled at various time-
This profound down-regulatory effect involved both 3.5 points thereafter to monitor sALT levels, and livers were
and 2.1 kb HBV mRNAs and lasted beyond day 14 in all harvested 7 days later. The polyclonal CTLs caused a
of the animals studied. At day 28, the suppressive effect modest elevation in sALT activity that was similar to
of the CTL began to subside, and HBV gene expression the injection of 2.5 3 106 CTL clones (see Figure 1A)
started to reappear, particularly in one animal. Densito- and subsided within 5 days (data not shown). Impor-
metric analysis of the autoradiographs (data not shown) tantly, as illustrated in Figure 5B, HBV DNA replicative
revealed that the hepatic steady-state content of HBV forms completely disappeared from the liver of these
mRNA of all the animals at days 5, 7, 10, and 14 was transgenic mice compared with saline-injected controls,
reduced by more than 95%, while the expression of as did hepatocellular cytoplasmic HBcAg (data not
housekeeping genes (e.g., GAPDH, rpL32, and b-actin), shown). Similar to the effect of 2.5 3 106 CTL clones (see
liver-specific transcription factors (HNF3a and HNF3b) Figure 1C), the CTL line was more effective at reducing
and liver-specific genes (e.g., albumin and transthyretin) hepatic HBV DNA replicative intermediates than HBV
were quantitatively unaffected by the CTL (data not RNA (Figure 5A).
shown).
These changes in hepatic HBV gene expression and
Perforinless CTLs Abolish HBV Replicationreplication were reflected by a commensurate disap-
without Killing the Hepatocytespearance of circulating virions, measured as HBV DNA
To evaluate the extent to which the antiviral effect ofin pooled serum from groups of three mice at each
CTL reflects destruction of HBV-positive hepatocytes,timepoint (data not shown). Not surprisingly, serum HBV
we injected HBsAg-specific H-2d-restricted CD81 CTLDNA content disappeared somewhat more slowly than
clones derived from HBsAg-primed perforin knockoutthe hepatic HBV DNA replicative intermediates. Con-
mice (KaÈ gi et al., 1994) into the HBV transgenic animals.comitant with the reappearance of hepatic HBV DNA in
These clones produce wild-type levels of IFNg and TNFaone mouse 4 weeks after CTL administration (Figure 4),
mRNA following in vitro activation with plate-bound anti-the serum HBV DNA content returned to preinjection
CD3e monoclonal antibody (MAb) (data not shown). Fourlevels at the same timepoint (data not shown).
age-, sex- and serum HBsAg-matched transgenic mice
from lineage 1.3.32 were injected intravenously with 107HBsAg-Specific Polyclonal Cell Lines Also
HBsAg-specific perforinless CTL (clone PKO-1), bled atDown-Regulate HBV Gene Expression
various timepoints thereafter, and sacrificed 5 daysand Replication
later. As shown in Figure 6B, the perforinless CTLTo determine whether the CTL clones we used in this
caused virtually no elevation in sALT activity comparedstudy reflect the functional potential of the HBsAg-spe-
cific CTL response in general, we monitored the effects with the injection of the same number of wild-type CTL
Immunity
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Figure 6. Effect of Perforinless HBV-Specific CTL on HBV Replica-
Figure 5. Effect of an HBV-Specific Polyclonal Cell Line on HBV tion and Liver Disease in Lineage 1.3.32
Gene Expression and Replication in Lineage 1.3.32 (A) Southern blot analysis of 20 mg of total liver DNA isolated from
(A) Northern blot analysis of 20 mg of total liver RNA isolated from four mice that were intravenously injected either with 107 wild-type
four mice that were intravenously injected with an HBsAg-specific CTL (clone 6C2) or with 107 perforinless HBV-specific CTL (clone
polyclonal CTL line(107 cells) andsacrificed 7 days later. The steady- PKO-1) and sacrificed 5 days later.HBV DNA content was compared
state HBV and GAPDH mRNA content was compared with total RNA with total DNA pooled from from 10 age-, sex-, and serum HBsAg-
pooled from 10 age-, sex-, and serum HBsAg-matched transgenic matched transgenic saline-injected controls. All DNA samples were
saline-injected controls. RNAse treated before gel electrophoresis. The filters were hybrid-
(B) Southern blot analysis of 20 mg of total liver DNA isolated from ized with a 32P-labeled HBV-specific DNA probe. DNA loading was
the same mice. HBV DNA content was compared with total DNA normalized by comparing the signal intensity of the integrated
pooled from the same controls described above. All DNA samples transgene DNA seen at the top of each lane.
were RNAse treated before gel electrophoresis. The filters were (B) sALT activity (6 SEM) after intravenous injection of wild-type
hybridized with a 32P-labeled HBV-specific DNA probe. DNA loading and perforinless HBV-specific CTL into the mice described above
was normalized by comparing the signal intensity of the integrated is expressed as units/liter.
transgene DNA seen at the top of each lane.
shown). To evaluate the magnitude and nature of the
(clone 6C2). Nevertheless, HBV DNA replicative forms intrahepatic inflammatory response and the intrahepatic
completely vanished from the liver of these transgenic cytokine induction profile following CTL administration,
mice compared with saline-injected controls (Figure 6A), we monitored CD3g, CD4, CD8a, and cytokine mRNA
as did hepatocellular cytoplasmic HBcAg (data not expression in the transgenic livers at multiple timepoints
shown), similar to the effect of wild-type CTL. This indi- following administration of clone 6C2. As shown in Fig-
cates that clearance of HBV DNA replicative forms from ure 7, very low levels of CD3g, CD4, CD8a, IL-1a, and
the liver does not require destruction of the hepatocyte. IL-1b were the only mRNA species detected in livers
from uninjected controls. Within 4±24 hr after CTL injec-
tion, however, the mRNA levels for these T cell markersIntrahepatic Cytokine Gene Expression in
CTL Clones and Transgenic Mouse Liver (especially CD8) and IL-1 increased dramatically (Figure
7A), and IFNg and TNFa mRNA appeared, despite littleafter CTL Administration
All CTL clones used herein were found to produce IFNg or no change in expression of other cytokines or a
housekeeping gene, rpL32, that was used as an internaland TNFa mRNA and protein using a multiprobe RNase
protection assay (Hobbs et al., 1993) and ELISA analysis control (Figure 7B). The induced transcripts remained
elevated for 72 hr and they decreased towards baseline(T. I. et al., unpublished data) following a 4 hr stimulation
in vitro with plate-bound anti-CD3e MAb (data not levels by day 5 (Figure 7B).
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Figure 8. IFNg and TNFa Mediate the Regulatory Effect of the CTLs
(A) Northern blot analysis of 20 mg of total liver RNA isolated from
groups of 2±3 age-, sex-, and serum HBsAg-matched lineage 1.3.32
mice that were intraperitoneally injected with 250 mg of IFNg and
TNFa MAb 24 hr before the CTL and sacrificed either 1 or 5 days
after CTL administration, as indicated. The latter group received a
second injection of 250 mg of IFNg and TNFa MAb 2 days after CTL
injection. Control mice were simultanously injected with 250 mg of
irrelevant hamster IgG. The steady-state HBV and GAPDH mRNA
content was compared with total RNA pooled from 10 age-, sex-,
and serum HBsAg-matched transgenic saline-injected controls.
(B) Southern blot analysis of 20 mg of total liver DNA isolated from
the same mice. HBV DNA content was compared with total DNAFigure 7. Analysis of Intrahepatic T Cell Markers and Cytokine
pooled from the same controls described above. All DNA samplesmRNA Expression in Lineage 1.3.32 at Varying Intervals after CTL
were RNAse treated before gel electrophoresis. The filters wereAdministration
hybridized with a 32P-labeled HBV-specific DNA probe. DNA loading
Total RNA (10 mg) extracted from the mice described in the legend was normalized by comparing the signal intensity of the integrated
to Figure 3 was analyzed by RNAse protection analysis for the ex- transgene DNA seen at the top of each lane.
pression of CD4, CD8, CD3g, and assorted cytokines as indicated.
Lanes 1 and 2 represent nontransgenic and transgenic resting livers,
and TNFa to modulate the cytopathic and regulatoryrespectively. The remaining lanes show intrahepatic cytokine gene
expression at varying times relative to CTL injection. The ribosomal effects of the CTL. Groups of mice were injected with
protein light 32 (L32) was used to normalize the amount of RNA IFNg MAb or TNFa MAb or both at various times relative
loaded in each lane. to the CTL, and were sacrificed 24 hr or 5 days after
CTL administration. Control mice were injected with ir-
relevant hamster immunoglobulin g (IgG). Northern andThe kinetics and magnitude of these changes reflect
the kinetics of CTL entry into the liver (maximal at 4 hr) Southern blot analysis was performed on total hepatic
RNA and DNA extracted either from these animals andand the recruitment of antigen-nonspecific inflammatory
cells (maximal at 24±72 hr) (Ando et al., 1993). The induc- from saline-injected controls.
As shown in Figure 8, simultaneous administrationtion of IFNg and TNFa in the liver 4 hr after CTL injection
(Figure 7B) coincides with the time when intrahepatic of IFNg and TNFa MAb completely blocked the CTL-
induced inhibition of hepatic HBV replication and geneCTL concentration reaches a stable plateau (Ando et
al., 1993). The minimal increase in T cell markers at this expression, and they also blocked the CTL-induced
clearance of HBcAg from the hepatocytes in the sametime (Figure 7A) confirms that very small numbers of
CTL actually enter the liver relative to the number of livers (data not shown). In contrast, each antibody was
only partially effective when administered individuallyHBV-positive hepatocytes (Ando et al., 1993). Nonethe-
less, these CTL are able to recruit a large number of host- (data not shown), thereby suggesting that the two cyto-
kines may activate independent regulatory pathwaysderived inflammatory cells, indicated by a significant
enhancement of T cell markers between 24±72 hr (Figure in the hepatocyte. Importantly, the antibodies did not
influence the severity of the liver disease induced by7A), associated with further induction of inflammatory
cytokines (Figure 7B). the CTL in these animals (data not shown), providing
additional evidence that the regulatory effect of CTL is
not due to destruction of the hepatocytes.CTL-Induced Suppression of HBV Gene
Expression and Replication Is Mediated
by IFNg and TNFa Discussion
To determine the extent to which IFNg and TNFa were
responsible for the CTL-induced effects in lineage In this study, we demonstrate that HBV nucleocapsid
particles, replicative DNA intermediates, and RNA can1.3.32,we monitoredthe ability of MAbs specific for IFNg
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be cleared from the liver of transgenic mice, and that of new virus and the synthesis of supercoiled HBV DNA
(Tuttleman et al., 1986), which is the normal transcrip-HBV virions can be cleared from the blood, by a series
of antiviral signals initially delivered by class I±restricted tional template of HBV during natural infection (see be-
low). Indeed, the 3.5 kb pregenomic RNA serves multipleHBsAg-specific CTL. We also demonstrate that the anti-
viral effect of the CTL is mediated by at least two inflam- indispensable functions in the viral life cycle, including
the production of the nucleocapsid particles and thematory cytokines and does not merely represent the
destruction of HBsAg-positive hepatocytes. There are replicative viral DNA forms that they contain (reviewed
by Ganem and Varmus, 1987). Obviously, by virtue ofseveral reasons why we believe these claims are valid.
First, clearance of viral nucleocapsids and replicative this function alone it would not be surprising if the syn-
thesis of new viral proteins and the assembly of newDNA intermediates begins prior to the onset of liver
disease, and eventually involves every hepatocyte in viral particles inan infected cell could be noncytolytically
abolished by the CTL response.these animals. Second, using wild-type CTL the disease
is relatively mild, consisting of only small sparsely scat- The complete disappearance of the 2.1 kb envelope
RNA further strengthens the antiviral potential of thetered necroinflammatory foci that kill a very small frac-
tion of the hepatocytes, while all traces of the virus CTL response in this model. We have previously re-
ported that recombinant TNFa down-regulates the(except the integrated transgene) disappear from virtu-
ally 100% of the hepatocytes. Third, the cytopathic and steady-state content of the 2.1 kb HBV envelope mRNA
in the hepatocytes of other lineages of transgenic miceregulatory effects of the CTL can be dissociated either
by the administration of antibodies to IFNg and TNFa, that only express this single gene product, and we have
shown that itdoes so by posttranscriptionally destabiliz-which completely abrogate the antiviral effect without
reducing disease severity, or by administration of ing this viral transcript (Gilles et al., 1992; Guilhot et al.,
1993). We have also found that the 2.1 kb HBV transcriptHBsAg-specific perforinless CTL, which completely ab-
rogate HBV replication without causing liver disease. is down-regulated in those animals, with delayed kinet-
ics, following the administration of the same CTL thatAdditionally, in related experiments to be reported sepa-
rately, we have shown that HBV gene expression and we used in the current study (Guidotti et al., 1994a).
Recently, we have also shown that the CTL-inducedreplication are abolished during persistent LCMV infec-
tion of the liver in response to the production of TNFa disappearance of both the 2.1 and 3.5 kb HBV tran-
scripts from the hepatocyte is primarly due to posttran-and type I interferons by LCMV-infected macrophages,
in the absence of any evidence of liver disease (Guidotti scriptional mechanisms that are focused on viral se-
quences located between nucleotides 1239±3157 (Tsuiet al., submitted).
The first detectable effect of the CTL on viral replica- et al., 1995).
Drawing upon the principles elucidated by this model,tion is the disappearance of cytoplasmic viral nucleo-
capsids and replicative DNA intermediates from the we propose that during HBV infection in man, virus-
specific CTLs recognize HBV antigens on the surfaceliver. The fact that these events occur prior to any de-
crease in viral RNA strongly suggests that at least two of infected hepatocytes and perform two distinct func-
tions. First, they kill a small fraction of infected hepato-antiviral pathways are activated in the hepatocytes by
the CTL: one that eliminates the nucleocapsids and their cytes, thereby causing the disease we recognize as viral
hepatitis. Second, they secrete IFNg and TNFa, therebycargo of replicative DNA intermediates and another that
down-regulates the RNA, which is transcribed from the curing all of the hepatocytes by the intracellular inactiva-
tion pathways described above. The extent to whichintegrated transgene. The similar kinetics with which the
viral nucleocapsid particles and replicative DNA inter- additional IFNg and TNFa produced by the antigen-non-
specific inflammatory cells that the CTL recruit or acti-mediates disappear from the cytoplasm suggest that
these two effects are related and that they lead to the vate in the liver contribute to this curative process re-
mains to be determined. While it is clear that HBV isclearance of virions from the blood.
The simplest explanations for these observations are exquisitely sensitive to this effect, the demonstration
of immunologically inducible intracellular inactivationthat the activated hepatocytes either prevent the forma-
tion of nucleocapsid particles or they accelerate their pathways for HBV in the hepatocyte, does not imply
that the same is true for all viruses and all cells. Althoughdegradation, causing them to release their content of
replicative intermediates into the cytoplasm, where they the literature suggests that many other viruses may also
be susceptible to intracellular inactivation by the im-are destroyed by endogenous nucleases. Of course,
it is also possible that the nucleocapsids are actively mune response, several factors must coexist for this
process to occur. First, the local immune response mustexported from the CTL-activated hepatocytes. This is
unlikely, however, in view of the disappearance of viral be vigorous enough to produce adequate amounts of
specific cytokines. Second, the infected cell must beDNA from the blood of the CTL-injected mice. Based on
these considerations, plus the known stability of HBcAg able to produce the appropriate antiviral activity in re-
sponse to the cytokines. Third, the virus life cycle mustparticles in Xenopus oocytes (Zhou and Standring, 1992)
and duck hepatocytes (Yu and Summers,1994), we favor include functions that are susceptible to those antiviral
factors.the degradation hypothesis, but additional experiments
are needed to clarify this interesting observation. The ultimate impact of these cytokine-mediated ef-
fects on HBV gene expression and viral replication onThe disappearance of the viral RNA from the liver
following CTL administration also represents an im- the outcome of HBV infection is a question of consider-
able importance that remains to be resolved. Impingingportant antiviral effect, since it precludes the production
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on this question are several aspects of HBV molecular play an important role in viral clearance in that model.
and immunobiology, in addition to its susceptibility to It is noteworthy that in the present experiments, HBV
cytokines, especially the involvement of hepatocellular gene expression and replication were completely abol-
destruction and regeneration to HBV clearance and the ished following the transfer of cytokine-producing per-
stability of the episomal HBV genome in the infected forinless CTL in the total absence of liver disease or
hepatocyte during an immune response. These issues hepatocellular regeneration, indicating that these HBV
merit discussion. products can be eliminated from living nondividing he-
The hypothesis that the clearance of HBV from the patocytes.
liver during acute viral hepatitis requires the destruction Finally, it is important to emphasize that total clear-
of all of the infected cells should be considered in the ance of HBV from infected cells requires more than inhi-
context of two underappreciated aspects of HBV infec- bition of viral gene expression and replication. Absolute
tion. First, HBV clearance occurs quite rapidly in most clearance requires elimination of the episomal cova-
infected patients, as well as in woodchucks (Kajino et lently closed circular (ccc) HBV DNA species that serves
al., 1994) and ducks (Jilbert et al., 1992) that have been as the viral transcriptional template in the nucleus of
massively infected by their corresponding hepadnavi- infected cells (Tuttleman et al., 1986). This aspect of
ruses, without massive destruction of the liver. Second, the HBV life cycle cannot be approached in the HBV
the number of potentially infected hepatocytes in the transgenic mouse model because, for unknown rea-
human liver (z1 3 1011) is not much less than the total sons, they do not produce ccc DNA (Guidotti et al.,
body lymphocyte population (z1 3 1012), and it is roughly 1995). Thus, we cannot determine whether the ccc DNA
equal to the total body CTL population, since only z25% is also susceptible to cytokine-mediated control in this
of total lymphocytes are CD81. Therefore, rapid destruc- model. However, since ccc DNA is abolished in the mas-
tion of all infected hepatocytes would require the rapid sive WHV infection model described above (Kajino et
commitment and deployment of an extraordinarily high al., 1994) in the absence of massive destruction or re-
proportion of the total body CTL into the liver. We view generation of hepatocytes and in thepresence of inflam-
this to be an unlikely scenario, since HBV epitope-spe- matory cells and Kupffer cell hyperplasia, it is likely that
cific CTL precursor frequencies in the peripheral blood ccc DNA can indeed be abolished from the resting hepa-
of acutely infected patients are usually in the 1024 to tocyte by cytokine-dependent pathways like those de-
1025 range (Chisari and Ferrari, 1995). The likelihood of scribed in the current study. If this is correct, the noncy-
this scenario is further diminished if one considers the tolytic antiviral processes described in this paper are
constraints to CTL movement in a solid organ like the likely to play a central role in viral clearance during HBV
liver and the possibility that the greatly outnumbered infection. According to this scenario, viral clearance may
CTLs may even be triggered to undergo apoptosis when be principally a CTL-inducible survival function of the
antigen is presented to them by infected epithelial cells infected cells rather than simply a destructive function
in the absence of strong costimulatory signals. Thus, of the immune response. If ccc DNA is not controllable
the potential for a single CTL to kill many infected hepa- by these mechanisms, they could paradoxically contrib-
tocytes in vivo may be much less than the cytolytic ute to viral persistence by reducing the visibility of HBV
capacity of the same CTL in vitro, where highly sensitive by the immune response while leaving theviral transcrip-
target cells are exposed to unphysiologically large num- tional template in place.
bers of effector cells in a cell pellet where there are no
structural barriers to CTL movement. Additionally, in
view of the rapidity of HBV clearance and the high pro- Experimental Procedures
portion of infected hepatocytes in the liver, the cytode-
structive CTL response should be regularly accompa-
HBV Transgenic Micenied by fulminant hepatitis and death, and it is not.
The HBV transgenic mice used in this study contain a terminallyBecause the liver has extraordinary regenerative ca-
redundant copy of the complete HBV genome (ayw subtype) that
pacity, when some hepatocytes are destroyed other he- extends from nucleotide 1068 just upstream of the viral enhancer I
patocytes are triggered to divide (Michalopoulos, 1990). and X promoter completely around the viral genome to nucleotide
If HBV cannot survive in a regenerating hepatocyte, this 1982 just downstream of the unique polyadenylation site, as pre-
viously described (Guidotti et al., 1995). The hepatocytes from theseprocess could also lead to viral clearance. Importantly,
animals replicate the virus at levels comparable to that seen in theFourel et al. (1994) have recently reported that clearance
infected livers of patients with chronic hepatitis without any evi-of persistent duck hepatitis B virus (DHBV) during antivi-
dence of cytopathology (Guidotti et al., 1995). Lineages 1.3.32 (offi-ral therapy required drug toxicity, i.e., liver cell necrosis,
cial designation, Tg[HBV 1.3 genome]Chi32) and 1.3.46 (official des-
inflammation, Kupffer cell activation, and hepatocyte ignation, Tg[HBV 1.3 genome]Chi46) were expanded by repetitive
turnover. While the authors emphasized the importance back crossing against either the C57BL/6 or the B10.D2 parental
of hepatocellular regeneration for viral clearance in strains, respectively, according to the genetic background of the
founder. Lineage 1.3.32 mice wereroutinely backcrossed one gener-these studies, inflammation and macrophage (Kupffer
ation against B10.D2 to produce H-2b3d F1 hybrids prior to injectioncell) activation may have also contributed to this effect.
of B10.D2-derived polyclonal cell lines and CTLs. Weanlings wereIn an independent study, the same investigators demon-
screened by analysis of serum for HBsAg and HBeAgusing commer-
strated that WHV clearance for the woodchuck liver is cially available reagents (Abbott Laboratories, Abbott Park, Illinois)
mostly independent of hepatocellular destruction and as previously described (Chisari et al., 1986), and 8- to 9-week-old
regeneration during massive acute WHV infection (Ka- males that were positive for both antigens were used for these
studies.jino et al., 1994), suggesting that other factors might
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Polyclonal T Cell Lines and CTL Clones Immunohistochemical Analysis
The intracellular distribution of HBcAg and PCNA was assessed bySeveral independently derived Ld-restricted CD31 CD42 CD81 CTL
the labeled avidin±biotin detection procedure as previously de-clones that recognize an epitope (IPQSLDSWWTSL) located be-
scribed (Guidotti et al., 1994c). In brief, paraffin-embedded sectionstween residues 28±39 of HBsAg, and secrete IFNg and TNFa follow-
in phosphate-buffered saline (PBS, pH 7.4) were treated for 10 mining antigen stimulation in vitro (Guidotti et al., 1994a) were used
at 378C with 3% hydrogen peroxide and washed with PBS. Sectionsin this study. They were maintained by weekly restimulation with
were blocked with normal goat serum, and rabbit anti-HBc/eAg orirradiated P815 cells that stably express the HBV large envelope
mouse anti-PCNA (Dako, Carpinteria, California) primary antiseraprotein (ayw subtype) containing HBsAg, as previously described
were applied at a 1:100 dilution for 60 min at 378C (HBcAg) or(Ando et al., 1994). The CTL clones were washed, counted, sus-
overnight at 48C (PCNA). After washing with PBS, a secondary anti-pended in HBSS containing 2% fetal calf serum 5 days after the
sera of biotin-conjugated goat anti-rabbit IgG F(ab9)2 (HBc/eAg) orlast stimulation, and injected intravenously into the transgenic mice
biotin-conjugated goat anti-mouse IgG F(ab9)2 (Sigma Corporation,and into their nontransgenic littermates as controls.
St. Louis, Missouri) were applied at a 1:100 dilution for 30 min atCTL lines were derived from spleen cells from nontransgenic
378C. The antibody-coated slides were washed with PBS, treatedB10.D2 mice immunized and stimulated weekly as described (Ando
with streptavidin±horseradish peroxidase conjugate (extravidin,et al., 1994). After 2 weeks of in vitro stimulation, the polyclonal cell
Sigma, St. Louis, Missouri) at a 1:600 dilution for 30 min at 378C,lines were tested for Ag-specific cytotoxic activity, analyzed by flow
stained with 3-amino-9-ethyl carbazole (Shandon-Lipshaw, Pitts-cytometry (over 80% were CD81), washed, counted, suspended in
burgh, Pennsylvania) (HBcAg) or 3,39-diaminobenzidine tetrahydro-HBSS containing 2% fetal calf serum, and injected intravenously
chloride (Sigma) (PCNA) and counterstained with Mayer's hematox-into transgenic mice from lineage 1.3.32 andnontransgenic controls.
ylin (HBcAg) or nuclear Fast Red (PCNA) before mounting.Perforinless CTL were produced by repetitive immunization of per-
forin knockout mice (KaÈ gi et al., 1994) with a recombinant vaccinia
DNA Analysisvirus that expresses HBsAg, exactly as described for the foregoing
DNA Isolation and Southern BlotCTL lines and clones. Following cloning by limiting dilution, an Ld-
Southern blot analysis was performed on total liver DNA from lin-restricted HBsAg 28±39-specific CD81 IFNg- and TNFa-producing
eages 1.3.32 and 1.3.46 by agarose gel electrophoresis of 20 mg ofCTL clone (PKO-1) that kills stably transfected P815 cells that ex-
restricted genomic DNA as previously described (Guidotti et al.,press HBsAg (Ando et al., 1994) was selected for injection into the
1995). Before electrophoresis, all DNA samples were digested withtransgenic mice.
RNAse A (Boehringer Mannheim, Indianapolis, Indiana) at 10 mg/ml
for 1 hr at 378C. Nylon filters were hybridized with a HBV-specific
32P-radiolabeled DNA probe as previously described (Guidotti et al.,Anti-Cytokine MAbs
1994b).Hamster MAb H22 (endotoxin 0.25 EU/mg by the limulus amebocyte
assay) and TN3 19.12 (0.5 EU/ml by the limulus amebocyte assay),
RNA Analysisspecific for murine IFNg and TNFa, respectively (Schreiber et al.,
Northern Blot Analysis1985; Sheehan et al., 1989), were used in this study. Purified hamster
Frozen tissues were mechanically pulverized and extracted by theIgG (Jackson Immune Research, West Grove, Pennsylvania) was
acid±guanidium phenol±choloroform method (Chomczynski andused as a control antibody. All antibodies were diluted to a concen-
Sacchi, 1987). Total RNA (20 mg) was analyzed for HBV, GAPDH,tration of 1250 mg per ml with nonpyrogenic phosphate-buffered
albumin expression by Northern Blot as previously described (Gui-saline (GIBCO BRL, Gaithersburg, Maryland) immediately before
dotti et al., 1994b).
injection. Antibodies (200 ml) were administered intraperitoneally 24
RNase Protection Assay
hr before and 2 days after the intravenous injection of the CTL.
The RNase protection assay for quantiation of mRNA was performed
exactly as described (Hobbs et al., 1993). The mouse IL-1a (B),
mIL-1b (A), mIL-2 (A), mIL-3 (B), mIL-4 (B), mIL-5 (C), mIL-6 (B),
Serological and Biochemical Analysis
mIFNg (B), mTNFa (A), mTNFb (A), and mL32(A) subclones in pGEM-
Serum was examined for HBsAg, HBeAg, and anti-HBs titer using
4 transcription vector were described in a previous report (Hobbs
commercially available reagents (Abbott Laboratories) and, in se- et al., 1993). The mCD4 (IC) (GenBank release 88; accession number
lected cases, HBsAg and HBeAg were quantitated by comparison M36850; nucleotides 233±523) and mCD3g (IC) (accession number
with known standards (Abbott Laboratories; Sorin, Saluggia, Italy) J03590; nucleotides 1643±1694 in exon 1, 42±65 in exon 2, and
as previously described (Chisari etal., 1986). Serum DNAse-resistant 42±166 in exon 3) subclones in pGEM-4 were prepared using poly-
HBV DNA was measured by dot-blot analysis exactly as decribed merase chain reaction±assisted cloning (Hobbs et al., 1993). The
(Guidotti et al., 1995). Hepatocellular injury was monitored by mea- mCD8a (DM) subclone in the pGEM-4 (which protects a 350 nt
suring sALT activity (Chisari et al., 1989). Results were expressed mRNA fragment) was provided by Dr. R. Hyman (The Salk Institute,
as mean sALT activity 6 SEM. To estimate the fraction of hepato- La Jolla, California). The subclones were linearized with EcoRI and
cytes killed during the CTL-induced liver disease, we compared the were used in template sets for T7 polymerase-directed synthesis
sALT profiles of CTL-injected mice with the profile obtained after of 32P-labeled antisense RNA probes. The hybridization reactions,
the intravenous injection of a known amount of solubilized liver RNAse treatments, isolations of protected RNA duplexes, and reso-
extract prepared from an 8-week-old normal male mouse liver. To lution of protected probes by denaturing PAGE gels were as de-
prepare the extract, the liver was homogenized by 10±20 strokes scribed (Hobbs et al., 1993). Dried gels were placed on film (XAR,
in a Potter±Elvehjem tissue grinder in ice-cold TE buffer (10 mM Kodak) with intensifyng screens for various periods of time at 2708C.
Tris±acetate [pH 8], 10 mM EDTA). Nonidet P-40 (Sigma Corporation, In Situ Hybridization
St. Louis, Missouri, final concentraion 1%) was added and after a This procedure was carried out exactly as described (Guidotti et
30 min incubation on ice the sample was centrifuged to remove the al., 1995). The 33P-labeled RNA probes used in this study span se-
nuclei and cellular debris. Aliquots corresponding to 1/15 of the quences on the noncoding and coding strand of HBV between resi-
whole liver extract (6.7% of the liver) were injected intravenously dues 1243±1948 as previously described (Guidotti et al., 1995).
into three nontransgenic mice and sALT activity was measured at
timed intervals thereafter. Protein Analysis
Immunoblot Analysis
Serum and organ homogenates wereprepared as described (Chisari
Histological Analysis et al., 1986). HBV precore and core protein expression was detected
Tissue samples were fixed in 10% zinc-buffered formalin (Anatek, by Western blot (immunoblotting) as previously described (Chisari
Limited, Battle Creek, Michigan), embedded in paraffin, sectioned et al., 1986). In brief, whole tissue powder was denatured in 100
(3 mm),and stained with hematoxylin and eosin as described (Chisari mM Tris±acetate (pH 6.8), 2.5% SDS, boiled, centifuged, and total
soluble protein was determined by Coomassie blue G-250 bindinget al., 1989).
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(BioRad). Total liver protein extracts (100 mg) were separated by an immunodominant viral cytotoxic T lymphocyte epitope. J. Immu-
nol. 149, 3331±3338.SDS 15% polyacrylamide gel electrophoresis and transferred onto
nitrocellulose membranes (Amersham, Arlington Heights, Illinois). Gilles, P.N., Fey, G., and Chisari, F.V. (1992). Tumor necrosis factor-
Filters were blocked with 5% nonfat dry milk (BioRad, Hercules, alpha negatively regulates hepatitis B virus gene expression in
California) in TBS (50 mM Tris±acetate [pH 7.6] 150 m NaCl) for 2 transgenic mice. J. Virol. 66, 3955±3960.
hr at room temperature. To detect core/precore antigens, rabbit anti-
Guidotti, L.G., Ando, K., Hobbs, M.V., Ishikawa, T., Runkel, L.,HBc/eAg (Dako) primary antiserum was applied at a 1:500 dilution in
Schreiber, R.D., and Chisari, F.V. (1994a). Cytotoxic T lymphocytesTBS overnight at room temperature, washed three times for 15 min
inhibit hepatitis B virus gene expression by a noncytolytic mecha-in TBS, and detected by incubation with a 125I-labeled donkey anti-
nism in transgenic mice. Proc. Natl. Acad. Sci. USA 91, 3764±3768.rabbit IgG (Amersham) for 1 hr at room temperature. Total liver
Guidotti, L.G., Guilhot, S., and Chisari, F.V. (1994b). Interleukin-2protein extracts from nontransgenic littermates, and recombinant
and alpha/beta interferon down-regulate hepatitis B virus gene ex-HBcAg (Sorin, Saluggia, Italy) were used as negative and positive
pression in vivo by tumor necrosis factor±dependent and indepen-controls, respectively.
dent pathways. J. Virol. 68, 1265±1270.
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